11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
During the pandemic there has been an increasing use of pre-publication reports and presentations at scientific meetings for the release of potentially significant treatment change. This has meant that the normal checks and balances with independent review prior to audited publication have not always occurred.
For urgent circumstances such practice may be appropriate. However, this trend is not confined to the COVID-19 pandemic but also is becoming common for much basic medical research. This article looks at 11 presentations at the recent European Society of Medical Oncology meeting and notes errors in the reports, which raise doubt about the value of the work.
Of the 11 presentations, 2 did not comply with the initial study design, none took account of loss to follow up and none addressed the issue of crossover, which may have induced patients to join trials. The authors say that without proper peer review and transparent presentation of results many seemingly important studies should be viewed with caution.
No comments:
Post a Comment